BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 18317762)

  • 1. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
    Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
    Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
    Ali BH; Al Moundhri MS
    Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin: a review of toxicities and therapeutic applications.
    Barabas K; Milner R; Lurie D; Adin C
    Vet Comp Oncol; 2008 Mar; 6(1):1-18. PubMed ID: 19178659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Can cisplatin renal toxicity be prevented?].
    Brillet G; Deray G; Bunker D; Ben Hmida M; Baumelou A; Jacobs C
    Nephrologie; 1991; 12(3):143-6. PubMed ID: 1922654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [About side effects of platinum drugs].
    Waszkiewicz K
    Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
    Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
    Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
    Hayek M; Srinivasan A
    Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
    [No Abstract]   [Full Text] [Related]  

  • 8. [Renal complications of anti-cancer chemotherapy].
    Fillastre JP; Moulin B; Godin M; Josse S
    Pathol Biol (Paris); 1986 Nov; 34(9):1013-28. PubMed ID: 3543812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to keep kidneys safe while shrinking tumors: the conundrum of cisplatin action.
    Goligorsky MS
    Am J Physiol Renal Physiol; 2007 Jul; 293(1):F50-1. PubMed ID: 17507601
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
    Dana R; Kachhwaha VS
    Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity of common drugs used by urologists.
    Bennett WM; Porter GA
    Urol Clin North Am; 1990 Feb; 17(1):145-56. PubMed ID: 2407013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity of cancer treatment.
    Lydon J
    Oncol Nurs Forum; 1986; 13(2):68-77. PubMed ID: 3633578
    [No Abstract]   [Full Text] [Related]  

  • 13. 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats.
    Tikoo K; Ali IY; Gupta J; Gupta C
    Toxicol Lett; 2009 Dec; 191(2-3):158-66. PubMed ID: 19723570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anticancer drugs used in medicine and being in clinical research].
    Malinowska K; Modranka R; Kedziora J
    Pol Merkur Lekarski; 2007 Sep; 23(135):165-9. PubMed ID: 18080687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxicity from chemotherapy: prevention and management.
    Vogelzang NJ
    Oncology (Williston Park); 1991 Oct; 5(10):97-102, 105; disc. 105, 109-11. PubMed ID: 1838278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity.
    Chirino YI; Pedraza-Chaverri J
    Exp Toxicol Pathol; 2009 May; 61(3):223-42. PubMed ID: 18986801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of cisplatin nephrotoxicity in cancer: adjusting the dosage with a computerized chrono-pump].
    Gestin-Boyer C; René C; Cupissol D; Tep A; Bressolle F; Bres J; Brun S; Serrou B; Pujol H
    C R Seances Soc Biol Fil; 1989; 183(3):263-8. PubMed ID: 2532561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects of cytotoxics-platinum agents.
    Selvaratnam G; Philips RH; Mohamed AK; Radzi A
    Adverse Drug React Toxicol Rev; 1997 Aug; 16(3):171-97. PubMed ID: 9512763
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prevention and management of nephrotoxicity from anti-cancer agents].
    Miyazaki J; Kawai K
    Nihon Rinsho; 2003 Jun; 61(6):973-7. PubMed ID: 12806945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern methods for diagnosis and monitoring of nephrotoxicity during antitumor therapy with platinum derivatives.
    Lyubimova NV; Topchieva SV; Averinova SG; Kashkadaeva AV; Gorbunova VA; Shiryaev SV; Kushlinskii NE
    Bull Exp Biol Med; 2000 Sep; 130(9):886-91. PubMed ID: 11177273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.